Download PDF
Horm Metab Res 2025; 57(01): 55-66
DOI: 10.1055/a-2458-7088
Original Article: Endocrine Care

Prediction of the Survival Status, Immunotherapy Response, and Medication of Lung Adenocarcinoma Patients Based on Hypoxia- and Apoptosis-Related Genes

Ziliang Shi
1   Thoracic Surgery, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China
,
Zi Sang
1   Thoracic Surgery, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China
,
Junmeng Xiao
1   Thoracic Surgery, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China
,
Jianbin Hou
1   Thoracic Surgery, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China
,
Mingfei Geng
1   Thoracic Surgery, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

To predict patient survival prognosis, we aimed to establish a novel set of gene features associated with hypoxia and apoptosis. RNA-seq and clinical data of LUAD were sourced from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, while hypoxia and apoptosis-related genes were obtained from the Molecular Signatures Database (MsigDB). A 13-gene-prognostic model incorporating hypoxia and apoptosis genes was developed using univariate/multivariate Cox regression, Nonnegative Matrix Factorization (NMF) clustering, and LASSO regression. Patients were divided into high-risk (HR) and low-risk (LR) groups according to the median risk score. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses revealed distinct biological processes between HR and LR groups, including hormone regulation and lipid metabolism pathways. Single sample gene set enrichment analysis (ssGSEA) indicated elevated cell infiltration levels of Neutrophils and T_helper_cells in the LR group, while NK cells and Th1cells were higher in the HR group. Immunophenoscore (IPS) and tumor immune dysfunction and exclusion (TIDE) analyses suggested potential benefits of immunotherapy for LR group patients. In conclusion, this prognostic feature integrating hypoxia- and apoptosis-related genes offers insights into predicting survival, immune status, and treatment response in LUAD patients, paving the way for personalized treatment strategies.

Keywords

lung adenocarcinoma - hypoxia - immunity - apoptosis - gene pairs - prognosis

Supplementary Material

Appendix_Tables_Suppl



Publication History

Received: 24 May 2024

Accepted after revision: 23 October 2024

Article published online:
22 November 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Siegel RL, Miller KD, Wagle NS. et al. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48
    CrossrefPubMedSearch in Google Scholar
  • 2 Travis WD, Brambilla E, Nicholson AG. et al. The 2015 World health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015; 10: 1243-1260
    CrossrefPubMedSearch in Google Scholar
  • 3 Krol K, Mazur A, Stachyra-Strawa P. et al. Non-small cell lung cancer treatment with molecularly targeted therapy and concurrent radiotherapy – a review. Int J Mol Sci 2023; 24: 5858
    CrossrefPubMedSearch in Google Scholar
  • 4 Chalela R, Curull V, Enriquez C. et al. Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy. J Thorac Dis 2017; 9: 2142-2158
    CrossrefPubMedSearch in Google Scholar
  • 5 Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. BMJ 2021; 375: n2363
    CrossrefPubMedSearch in Google Scholar
  • 6 Hirsch FR, Scagliotti GV, Mulshine JL. et al. Lung cancer: current therapies and new targeted treatments. Lancet 2017; 389: 299-311
    CrossrefPubMedSearch in Google Scholar
  • 7 Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest 2022; 132: e159839
    CrossrefPubMedSearch in Google Scholar
  • 8 Jing X, Yang F, Shao C. et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer 2019; 18: 157
    CrossrefPubMedSearch in Google Scholar
  • 9 Fu R, Du W, Ding Z. et al. HIF-1alpha promoted vasculogenic mimicry formation in lung adenocarcinoma through NRP1 upregulation in the hypoxic tumor microenvironment. Cell Death Dis 2021; 12: 394
    CrossrefPubMedSearch in Google Scholar
  • 10 Yu F, Liang M, Huang Y. et al. Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling. J Exp Clin Cancer Res 2021; 40: 179
    CrossrefPubMedSearch in Google Scholar
  • 11 Wang P, Guan D, Zhang XP. et al. Modeling the regulation of p53 activation by HIF-1 upon hypoxia. FEBS Lett 2019; 593: 2596-2611
    CrossrefPubMedSearch in Google Scholar
  • 12 Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol 2019; 20: 175-193
    CrossrefPubMedSearch in Google Scholar
  • 13 Kashyap D, Garg VK, Goel N. Intrinsic and extrinsic pathways of apoptosis: Role in cancer development and prognosis. Adv Protein Chem Struct Biol 2021; 125: 73-120
    CrossrefPubMedSearch in Google Scholar
  • 14 Morana O, Wood W, Gregory CD. The apoptosis paradox in cancer. Int J Mol Sci 2022; 23: 1328
    CrossrefPubMedSearch in Google Scholar
  • 15 Yoon D, Bae K, Kim JH. et al. Oncogenic effect of the novel fusion gene VAPA-Rab31 in lung adenocarcinoma. Int J Mol Sci 2019; 20: 2309
    CrossrefPubMedSearch in Google Scholar
  • 16 Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nature reviews. Clin Oncol 2020; 17: 395-417
    CrossrefPubMedSearch in Google Scholar
  • 17 Yang W, Soares J, Greninger P. et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013; 41: D955-D961
    CrossrefPubMedSearch in Google Scholar
  • 18 Charoentong P, Finotello F, Angelova M. et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 2017; 18: 248-262
    CrossrefPubMedSearch in Google Scholar
  • 19 Jiang P, Gu S, Pan D. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 2018; 24: 1550-1558
    CrossrefPubMedSearch in Google Scholar
  • 20 Lareau S, Slatore C, Smyth R. Lung Cancer. Am J Respir Crit Care Med 2021; 204: P21-P22
    CrossrefPubMedSearch in Google Scholar
  • 21 Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis 2018; 9: 117
    CrossrefPubMedSearch in Google Scholar
  • 22 Imielinski M, Berger AH, Hammerman PS. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107-1120
    CrossrefPubMedSearch in Google Scholar
  • 23 Hu HB, Yang XP, Zhou PX. et al. High expression of keratin 6C is associated with poor prognosis and accelerates cancer proliferation and migration by modulating epithelial-mesenchymal transition in lung adenocarcinoma. Genes Genom 2020; 42: 179-188
    CrossrefPubMedSearch in Google Scholar
  • 24 Gastelum G, Jiang W, Wang L. et al. Polycyclic aromatic hydrocarbon-induced pulmonary carcinogenesis in cytochrome P450 (CYP)1A1- and 1A2-null mice: roles of CYP1A1 and CYP1A2. Toxicol Sci 2020; 177: 347-361
    CrossrefPubMedSearch in Google Scholar
  • 25 Feng S, Cao H, Sui Y. et al. CDCA4 interacts with IGF2BP1 to regulate lung adenocarcinoma proliferation via the PI3K/AKT pathway. Thorac Cancer 2023; 14: 724-735
    CrossrefPubMedSearch in Google Scholar
  • 26 Boccellino M, Pinto F, Ieluzzi V. et al. Proteomics analysis of human serum of patients with non-small-cell lung cancer reveals proteins as diagnostic biomarker candidates. J Cell Physiol 2019; 234: 23798-23806
    CrossrefPubMedSearch in Google Scholar
  • 27 Xue GL, Zhang C, Zheng GL. et al. Annexin A13 predicts poor prognosis for lung adenocarcinoma patients and accelerates the proliferation and migration of lung adenocarcinoma cells by modulating epithelial-mesenchymal transition. Fundam Clin Pharmacol 2020; 34: 687-696
    CrossrefPubMedSearch in Google Scholar
  • 28 Hsu LH, Chu NM, Kao SH. Estrogen, estrogen receptor and lung cancer. Int J Mol Sci 2017; 18: 1713
    CrossrefPubMedSearch in Google Scholar
  • 29 Stabile LP, Rothstein ME, Cunningham DE. et al. Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. Carcinogenesis 2012; 33: 2181-2189
    CrossrefPubMedSearch in Google Scholar
  • 30 Taurino G, Chiu M, Bianchi MG. et al. The SLC38A5/SNAT5 amino acid transporter: from pathophysiology to pro-cancer roles in the tumor microenvironment. Am J Physiol Cell Physiol 2023; 325: C550-C562
    CrossrefPubMedSearch in Google Scholar
  • 31 Updegraff BL, Zhou X, Guo Y. et al. Transmembrane protease TMPRSS11B promotes lung cancer growth by enhancing lactate export and glycolytic metabolism. Cell Rep 2018; 25: 2223-2233 e2226
    CrossrefPubMedSearch in Google Scholar
  • 32 Liu J, Mazzone PJ, Cata JP. et al. Serum free fatty acid biomarkers of lung cancer. Chest 2014; 146: 670-679
    CrossrefPubMedSearch in Google Scholar
  • 33 Wang J, Zeng Y, Song J. et al. Perturbation of arachidonic acid and glycerolipid metabolism promoted particulate matter-induced inflammatory responses in human bronchial epithelial cells. Ecotoxicol Environ Saf 2023; 256: 114839
    CrossrefPubMedSearch in Google Scholar
  • 34 Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood 2019; 133: 2159-2167
    CrossrefPubMedSearch in Google Scholar
  • 35 Liew PX, Kubes P. The neutrophilʼs role during health and disease. Physiol Rev 2019; 99: 1223-1248
    CrossrefPubMedSearch in Google Scholar
  • 36 Hirschhorn D, Budhu S, Kraehenbuehl L. et al. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell 2023; 186: 1432-1447 e1417
    CrossrefPubMedSearch in Google Scholar
  • 37 Fan X, Shu P, Wang Y. et al. Interactions between neutrophils and T-helper 17 cells. Front Immunol 2023; 14: 1279837
    CrossrefPubMedSearch in Google Scholar
  • 38 Adotevi O, Dosset M, Galaine J. et al. Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine. Hum Vaccin Immunother 2013; 9: 1073-1077
    CrossrefPubMedSearch in Google Scholar
  • 39 Portale F, Di Mitri D. NK Cells in cancer: mechanisms of dysfunction and therapeutic potential. Int J Mol Sci 2023; 24: 9521
    CrossrefPubMedSearch in Google Scholar
  • 40 Chang X, Zhao J, Zhou Y. et al. MiR-7 deficiency promotes Th1 polarization of CD4(+)T cells and enhances the antitumor effect in adoptive cell therapy for lung cancer. Immunol Res 2024; 72: 134-146
    CrossrefPubMedSearch in Google Scholar